26 Sep SYNCROSOME WILL PARTICIATE TO THE 3RD ANNUAL NEUROSCIENCE R&D TECHNOLOGIES CONFERENCE
Our Scientific Manager, Sandra Robelet, will launch a talk on the new preclinical strategy combining in vitro and in vivo models to assess the drug efficacy of your compounds in Neurodegenerative disease and interact with Pharma and Biotech’s companies from all around the world.
This talk will evaluate in vitro and in vivo strategies in Parkinson and Stroke diseases. An other interesting point will be presented : the possibility we can propose you in CNS-PK (CSF sampling and Microdialysis with the monitoring of Neurotransmitters) that could complete the response of in vitro and in vivo disease models with a biochemical approaches of the disease.
Contact us if you want to read the presentation or discuss with us directly!